Phase I study of Irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia

Francis Giles, Jorge Cortes, Guillermo Garcia-Manero, Stephen Kornblau, Elihu Estey, Monica Kwari, Anthony Murgo, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

Irofulven (MGI 114, 6-hydroxymethylacylfulvene, HMAF) is a semisynthetic illudin analog with broad in vitro anti-neoplastic activity. In this leukemia phase I study, we investigated the toxicity profile and activity of Irofulven in patients with primary refractory or relapsed acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or myelodysplastic syndromes (MDS). Irofulven was given as an intravenous infusion over five minutes daily for five days. The starting dose was 10 mg/m2/day (50 mg/m2/course). Courses were scheduled to be given every 3-4 weeks according to toxicity and antileukemic efficacy. Twenty patients {AML: 17 patients; MDS: one patient; ALL: one patient; mixed lineage acute leukemia: one patient} were treated. Nausea, vomiting, hepatic dysfunction, weakness, renal dysfunction, and pulmonary edema were dose limiting toxicities, occurring in two of five patients treated at 20 mg/m2/day and two of three patients treated at 12.5 mg/m2/day. The MTD was defined as 10mg/m2/day for five days. One patient with primary resistant AML achieved complete remission. Proposed phase II studies will further define the activity of Irofulven in patients with better prognosis AML and in other hematological malignancies, both as a single agent and in combination regimens, particularly with topoisomerase 1 inhibitors.

Original languageEnglish (US)
Pages (from-to)13-20
Number of pages8
JournalInvestigational New Drugs
Volume19
Issue number1
DOIs
StatePublished - Mar 24 2001
Externally publishedYes

Fingerprint

Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Biphenotypic Acute Leukemia
acylfulvene
irofulven
Topoisomerase I Inhibitors
Pulmonary Edema
Hematologic Neoplasms
Intravenous Infusions
Nausea
Vomiting
Kidney
Liver

Keywords

  • Acute leukemia
  • Acylfulvene
  • Illudins
  • Irofulven
  • MGI 114
  • Phase I

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Phase I study of Irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia. / Giles, Francis; Cortes, Jorge; Garcia-Manero, Guillermo; Kornblau, Stephen; Estey, Elihu; Kwari, Monica; Murgo, Anthony; Kantarjian, Hagop.

In: Investigational New Drugs, Vol. 19, No. 1, 24.03.2001, p. 13-20.

Research output: Contribution to journalArticle

Giles, F, Cortes, J, Garcia-Manero, G, Kornblau, S, Estey, E, Kwari, M, Murgo, A & Kantarjian, H 2001, 'Phase I study of Irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia', Investigational New Drugs, vol. 19, no. 1, pp. 13-20. https://doi.org/10.1023/A:1006432012394
Giles, Francis ; Cortes, Jorge ; Garcia-Manero, Guillermo ; Kornblau, Stephen ; Estey, Elihu ; Kwari, Monica ; Murgo, Anthony ; Kantarjian, Hagop. / Phase I study of Irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia. In: Investigational New Drugs. 2001 ; Vol. 19, No. 1. pp. 13-20.
@article{a2415971076d41ff8eb2d40797506946,
title = "Phase I study of Irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia",
abstract = "Irofulven (MGI 114, 6-hydroxymethylacylfulvene, HMAF) is a semisynthetic illudin analog with broad in vitro anti-neoplastic activity. In this leukemia phase I study, we investigated the toxicity profile and activity of Irofulven in patients with primary refractory or relapsed acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or myelodysplastic syndromes (MDS). Irofulven was given as an intravenous infusion over five minutes daily for five days. The starting dose was 10 mg/m2/day (50 mg/m2/course). Courses were scheduled to be given every 3-4 weeks according to toxicity and antileukemic efficacy. Twenty patients {AML: 17 patients; MDS: one patient; ALL: one patient; mixed lineage acute leukemia: one patient} were treated. Nausea, vomiting, hepatic dysfunction, weakness, renal dysfunction, and pulmonary edema were dose limiting toxicities, occurring in two of five patients treated at 20 mg/m2/day and two of three patients treated at 12.5 mg/m2/day. The MTD was defined as 10mg/m2/day for five days. One patient with primary resistant AML achieved complete remission. Proposed phase II studies will further define the activity of Irofulven in patients with better prognosis AML and in other hematological malignancies, both as a single agent and in combination regimens, particularly with topoisomerase 1 inhibitors.",
keywords = "Acute leukemia, Acylfulvene, Illudins, Irofulven, MGI 114, Phase I",
author = "Francis Giles and Jorge Cortes and Guillermo Garcia-Manero and Stephen Kornblau and Elihu Estey and Monica Kwari and Anthony Murgo and Hagop Kantarjian",
year = "2001",
month = "3",
day = "24",
doi = "10.1023/A:1006432012394",
language = "English (US)",
volume = "19",
pages = "13--20",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Phase I study of Irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia

AU - Giles, Francis

AU - Cortes, Jorge

AU - Garcia-Manero, Guillermo

AU - Kornblau, Stephen

AU - Estey, Elihu

AU - Kwari, Monica

AU - Murgo, Anthony

AU - Kantarjian, Hagop

PY - 2001/3/24

Y1 - 2001/3/24

N2 - Irofulven (MGI 114, 6-hydroxymethylacylfulvene, HMAF) is a semisynthetic illudin analog with broad in vitro anti-neoplastic activity. In this leukemia phase I study, we investigated the toxicity profile and activity of Irofulven in patients with primary refractory or relapsed acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or myelodysplastic syndromes (MDS). Irofulven was given as an intravenous infusion over five minutes daily for five days. The starting dose was 10 mg/m2/day (50 mg/m2/course). Courses were scheduled to be given every 3-4 weeks according to toxicity and antileukemic efficacy. Twenty patients {AML: 17 patients; MDS: one patient; ALL: one patient; mixed lineage acute leukemia: one patient} were treated. Nausea, vomiting, hepatic dysfunction, weakness, renal dysfunction, and pulmonary edema were dose limiting toxicities, occurring in two of five patients treated at 20 mg/m2/day and two of three patients treated at 12.5 mg/m2/day. The MTD was defined as 10mg/m2/day for five days. One patient with primary resistant AML achieved complete remission. Proposed phase II studies will further define the activity of Irofulven in patients with better prognosis AML and in other hematological malignancies, both as a single agent and in combination regimens, particularly with topoisomerase 1 inhibitors.

AB - Irofulven (MGI 114, 6-hydroxymethylacylfulvene, HMAF) is a semisynthetic illudin analog with broad in vitro anti-neoplastic activity. In this leukemia phase I study, we investigated the toxicity profile and activity of Irofulven in patients with primary refractory or relapsed acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or myelodysplastic syndromes (MDS). Irofulven was given as an intravenous infusion over five minutes daily for five days. The starting dose was 10 mg/m2/day (50 mg/m2/course). Courses were scheduled to be given every 3-4 weeks according to toxicity and antileukemic efficacy. Twenty patients {AML: 17 patients; MDS: one patient; ALL: one patient; mixed lineage acute leukemia: one patient} were treated. Nausea, vomiting, hepatic dysfunction, weakness, renal dysfunction, and pulmonary edema were dose limiting toxicities, occurring in two of five patients treated at 20 mg/m2/day and two of three patients treated at 12.5 mg/m2/day. The MTD was defined as 10mg/m2/day for five days. One patient with primary resistant AML achieved complete remission. Proposed phase II studies will further define the activity of Irofulven in patients with better prognosis AML and in other hematological malignancies, both as a single agent and in combination regimens, particularly with topoisomerase 1 inhibitors.

KW - Acute leukemia

KW - Acylfulvene

KW - Illudins

KW - Irofulven

KW - MGI 114

KW - Phase I

UR - http://www.scopus.com/inward/record.url?scp=0035096161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035096161&partnerID=8YFLogxK

U2 - 10.1023/A:1006432012394

DO - 10.1023/A:1006432012394

M3 - Article

C2 - 11291829

AN - SCOPUS:0035096161

VL - 19

SP - 13

EP - 20

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -